Printer Friendly

GLAXO ANNOUNCES INITIATIVE FOR BETTER TB MEDICINES

 LONDON, April 22 /PRNewswire/ -- Glaxo is to establish a 10 million pound, five year international research program to find better treatments for TB. Discussions with academic institutions in the UK and overseas are well advanced and will lead to a collaborative research effort later this year.


The underlying aim of this research will be to bring the power of modern molecular biology to bear on the disease.
 Although the availability of anti-TB drugs and vaccines had led many to believe TB was under control, it is now considered to be a major health risk in industrialized nations as well as the third world.
 The Glaxo TB Initiative will comprise a highly focused industry/academia collaboration that will attempt to discover novel targets for drugs. Key areas of study will be the genetics, molecular biology and biochemistry of the enzymes involved in bacterial cell wall synthesis and, particularly the mechanism of drug resistance. The possibilities for better vaccines will also be explored. Glaxo will use information from this basic research to discover novel TB antibiotics or vaccines.
 Announcing the Initiative at the London School of Hygiene and Tropical Medicine's third annual public health forum ("Tuberculosis -- Back to the Future" April 18-21), Glaxo Deputy Chairman and Chief Executive Dr. Richard Sykes said: "Thoughrn biochemistry and molecular biology to point the way to new targets for drug action."
 Glaxo has already identified likely academic research partners and is presently discussing their TB research proposals. It is hoped the program will be finalized by this summer. In the light of the pressing public health need, the intention is to achieve a greater degree of interactive managed collaboration than is often the case in academic research. To this end, a Joint Research Body, led by Glaxo, will manage the overall program so that research is well focused, resources are used efficiently and communication of research findings between the collaborating centers is expedited. Reflecting the innovative nature of this initiative, the initial plans are for a minimum of five years, as opposed to the three years that is the norm for grants for research projects.
 -0- 4/22/93
 /CONTACT: Nancy Pekarek of Glaxo at Research Triangle Park, 919-248-2839/
 (GLX)


CO: Glaxo Holdings p.l.c. ST: IN: MTC HEA SU: PDT

CM -- CH001 -- 9250 04/22/93 09:40 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:385
Previous Article:GEORGIA POWER PRESIDENT TESTIFIES ON ENERGY TAX BEFORE SENATE COMMITTEE
Next Article:CURRENT TECHNOLOGY FINALIZES NEGOTIATIONS
Topics:


Related Articles
GLAXO TO OFFER PRICE DISCOUNTS TO PUBLIC HEALTH CLINICS
GLAXO INC., HOUGHTEN PHARMACEUTICALS SIGN JOINT RESEARCH, DEVELOPMENT AGREEMENT USING PATENTED PEPTIDE TECHNOLOGY IN DRUG DISCOVERY
GLAXO INITIATES LEGAL ACTION AFTER CALIFORNIA MEDICAID DECISION
GLAXO INC. NAMES EXECUTIVES TO NEW POSITIONS
GLAXO AND WARNER-LAMBERT ANNOUNCE OTC JOINT VENTURE
GLAXO WELLCOME SETS NEW GOALS FOR INVESTMENT IN INNOVATION; ZANTAC HELPS FUEL 2000% INCREASE IN R&D EXPENDITURES
GlaxoSmithKline Welcomes the Settlement of Industry Association Litigation Against the South African Government.
Paratek Inks Additional Research Collaboration for Tetracycline Program Researching Activity Against Resistant Tuberculosis.
The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa.
The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters